Medtronic's bid to gain US approval of its REVO Surescan pacemaker has been set back after an advisory panel to the FDA criticised a trial of the device. In documents prepared in advance of a meeting due to be held today, the FDA's circulatory system devices panel pointed out that ...
Please Login to read the full article.
